Skip to main content
Journal cover image

Neurosarcoidosis following Immune Checkpoint Inhibition.

Publication ,  Journal Article
Dunn-Pirio, AM; Shah, S; Eckstein, C
Published in: Case Rep Oncol
2018

Recently, immune checkpoint inhibitors have revolutionized cancer care by enhancing anti-tumor immunity. However, by virtue of stimulating the immune system, they can lead to immune-related adverse events (irAEs). Neurologic irAEs are uncommon but are becoming increasingly recognized and can be quite serious or even fatal. Furthermore, central nervous system (CNS) manifestations may be difficult to distinguish from CNS metastases, posing management challenges. Here, we describe a patient who developed exacerbation of sarcoidosis leading to CNS involvement following dual checkpoint blockade with nivolumab and ipilimumab for metastatic melanoma and review the relevant literature.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Case Rep Oncol

DOI

ISSN

1662-6575

Publication Date

2018

Volume

11

Issue

2

Start / End Page

521 / 526

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dunn-Pirio, A. M., Shah, S., & Eckstein, C. (2018). Neurosarcoidosis following Immune Checkpoint Inhibition. Case Rep Oncol, 11(2), 521–526. https://doi.org/10.1159/000491599
Dunn-Pirio, Anastasie M., Suma Shah, and Christopher Eckstein. “Neurosarcoidosis following Immune Checkpoint Inhibition.Case Rep Oncol 11, no. 2 (2018): 521–26. https://doi.org/10.1159/000491599.
Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following Immune Checkpoint Inhibition. Case Rep Oncol. 2018;11(2):521–6.
Dunn-Pirio, Anastasie M., et al. “Neurosarcoidosis following Immune Checkpoint Inhibition.Case Rep Oncol, vol. 11, no. 2, 2018, pp. 521–26. Pubmed, doi:10.1159/000491599.
Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following Immune Checkpoint Inhibition. Case Rep Oncol. 2018;11(2):521–526.
Journal cover image

Published In

Case Rep Oncol

DOI

ISSN

1662-6575

Publication Date

2018

Volume

11

Issue

2

Start / End Page

521 / 526

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis